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Background: miRNA-154 (miR-154) has been identified as a tumor suppressor in several types of human cancers.
However, its clinical significance in colorectal cancer (CRC) is still unclear. The aim of this study was to analyze the
association of miR-154 expression with clinicopathologic features and prognosis in CRC patients.
Methods: Quantitative RT-PCR was performed to evaluate miR-154 levels in 169 pairs of CRC specimens and
adjacent noncancerous tissues. Then, the associations of miR-154 expression with clinicopathological factors or
survival of patients suffering CRC were determined.
Results: The expression levels of miR-154 in CRC tissues were significantly lower than those in corresponding
noncancerous tissues (P < 0.001). Decreased miR-154 expression was significantly associated with large tumor size,
positive lymph node metastasis, and advanced clinical stage. Moreover, the univariate analysis demonstrated that
CRC patients with low miR-154 expression had poorer overall survival (P = 0.006). The multivariate analysis identified
low miR-154 expression as an independent predictor of poor survival.
Conclusions: These findings suggested that miR-154 downregulation may be associated with tumor progression of
CRC, and that this miR may be an independent prognostic marker for CRC patients.
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Colorectal cancer (CRC) ranks as the third most prevalent
cancer worldwide. Despite the clinical implementation of
numerous therapeutic strategies, it remains a leading
cause of cancer-related deaths due to therapy resistance
and metastasis [1]. Previous studies have demonstrated di-
verse genetic alterations in CRC, but the highly complex
molecular mechanisms underlying CRC carcinogenesis
and progression remain obscure. Therefore, it is necessary
to search novel markers for CRC, which can accurately
identify biological characteristics of tumors, improve
therapeutic strategies, and predict clinical outcome.
MicroRNAs (miRs) are a class of short (about 22
nucleotides in length), endogenous, single-stranded,
non-protein-coding RNAs that directly bind to the 3’-
untranslated regions (3’-UTRs) of target messenger RNAs
(mRNAs), leading to mRNA degradation or translational* Correspondence: manulinkl@163.com
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creativecommons.org/publicdomain/zero/1.0/suppression [2]. Beyond the involvement in diverse bio-
logical processes, including cell growth, apoptosis, devel-
opment, differentiation, and endocrine homeostasis [3],
emerging evidence strongly suggests that the deregulation
or dysfunction of miRs contributes to human carcinogen-
esis and cancer progression [4–6]. miRs can function as
either oncogenes or tumor suppressors according to the
roles of their target genes. In terms of CRC, abnormal ex-
pression of several miRs such as miR-27b, miR-133b, and
miR-124 have been reported [7–9]. Zhang et al. found that
ectopic expression of miR-224 promoted CRC tumor cell
proliferation, migration, and invasion in vitro [10]. Zheng
et al. indicated that downregulation of miR-132 in CRC
was associated with tumor size, distant metastasis, and
TNM stage [11]. Furthermore, miR-218, miR-378, miR-
378a-3p, and miR-378a-5p expressions were independent
prognostic factors for CRC patients [12–14]. miR-129 sen-
sitized CRC cells to 5-FU both in vitro and in vivo [15],
and miR-124 could increase the radiosensitivity of CRC
cells [16]. These findings suggest that miRs act not only asdistributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Table 1 Correlation between miR-154 expression and different





miR-154 expression P value
Low (n = 84) High (n = 85)
Age
<60 78 41 37 0.539
≥60 91 43 48
Gender
Male 98 51 47 0.534
Female 71 33 38
Tumor size (cm)
<5 95 39 56 0.013
≥5 74 45 29
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therapeutic targets of CRC.
Extensive researches have shown that miR-154 is
deregulated and functions as a candidate tumor suppres-
sor in some tumors such as hepatocellular carcinoma
and prostate cancer [17, 18]. Interestingly, Xin et al.
found that miR-154 was decreased in CRC tissues and
cell lines [19]. Ectopic expression of miR-154 remarkably
suppressed cell proliferation and colony formation, mi-
gration and invasion in CRC cells. However, the roles of
miR-154 in the progression of CRC and its underlying
potential to predict clinical outcome of patients with this
disease remain elusive. The aim of this study was to
analyze the association of miR-154 expression with clini-
copathologic features and prognosis in patients suffering
CRC.Histology/differentiation
Well + moderate 88 38 50 0.091
Poor 81 46 35
Depth of invasion
T1 + T2 64 28 36 0.268
T3 + T4 105 56 49
N classification
Negative 69 24 45 0.002
Positive 100 60 40
TNM stage
I 30 9 21 0.004
II 39 15 24
III 100 60 40Methods
Tissue samples and cell lines
This study was approved by the Research Ethics Com-
mittee of The First Affiliated Hospital of Wenzhou Med-
ical College. Written informed consent was obtained
from all of the patients. All specimens were handled and
made anonymous according to the ethical and legal
standards.
A total of 169 pairs of primary CRC and adjacent non-
cancerous tissues were obtained from patients who
underwent surgery at The First Affiliated Hospital of
Wenzhou Medical College between January 2006 and
December 2008. None of the patients had received
chemotherapy or radiotherapy before surgery excision.
After collection, all tissue samples were immediately fro-
zen in liquid nitrogen and stored at −80 °C until use.
The patients’ information is summarized in Table 1. All
of the patients received follow-up. Overall survival was
defined as the time from primary surgery to death of the
patient or, for living patients, the date of last follow-up.RNA extraction and quantitative real-time PCR
Total RNA was extracted from clinical specimens with
Trizol reagent (Invitrogen Corp, Carlsbad, CA, USA) ac-
cording to the manufacturer’s instructions. RNA con-
centration was measured using NanoDrop (Thermo
Scientific). Ten nanograms of total RNA was transcribed
into cDNAs using a TaqMan MicroRNA Reverse Tran-
scription Kit (Applied Biosystems, Foster City, CA,
USA). Real-time PCR was performed with a Taqman
MicroRNA Assay Kit (Applied Biosystems) on ABI7500
real-time PCR detection system. The PCR program for
detecting miRs was as follows: 50 °C for 2 min, 95 °C for
10 min, 40 cycles of 95 °C for 15 s, and 60 °C for 1 min.
U6 small nuclear RNA was used as an internal control.
Each sample was measured in triplicate, and the relativeamount of miR-154 to U6 was calculated using the
equation 2−ΔCt, where ΔCT = (CTmiR−154 − CTU6).
Statistics
All statistical analyses were carried out using the SPSS
16.0 software package (SPSS, Chicago, IL, USA). Data
were presented as mean ± standard deviation (SD). Differ-
ences between groups were analyzed using the Student’s
t-test or chi-square test. The postoperative survival rate
was analyzed with Kaplan-Meier method, and differences
in survival rates were assessed with log-rank test. A Cox
proportional hazards model was used for multivariate ana-
lysis. P < 0.05 was considered to be statistically significant.
Results
Downregulation of miR-154 in human CRC tissues
The expression levels of miR-154 were detected in 169
pairs of CRC and corresponding adjacent noncancerous
tissues normalized to U6 small nuclear RNA. As shown
in Fig. 1, the expression levels of miR-154 in CRC tissues
were found to be distinctly decreased compared to non-
cancerous tissues. The results showed that the relative
Fig. 1 MiR-154 expression was significantly lower in colorectal cancer samples than in the corresponding noncancerous tissues (P < 0.001, paired
t-test). MiR-154 expression levels were calculated by the 2−ΔCt method and normalized to U6 small nuclear RNA
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8.92 ± 2.12) was significantly lower than that in corre-
sponding noncancerous tissues (mean ± SD: 19.36 ± 4.35;
P < 0.001).
Downregulation of miR-154 associates with advanced
clinicopathological features of CRC
The associations of miR-154 expression with various
clinicopathological parameters of CRC tissues were ana-
lyzed. The patients were divided into two groups accord-
ing to their miR-154 expression levels, using the median
of miR-154 expression in all 169 patients as a cutoff:
high miR-154 expression group (n = 85) and low miR-
154 expression group (n = 84). As shown in Table 1, miR-
154 was significantly downregulated in CRC patients withFig. 2 Kaplan-Meier survival curves of patients with colorectal cancer based
had significantly poorer prognosis than those in high expression group (P =large tumor size (P = 0.013), positive lymph node metasta-
sis (P = 0.002), and advanced clinical stage (P = 0.004). No
significant difference was observed between miR-154 ex-
pression and patients’ age, gender, tumor differentiation,
and depth of invasion.
Downregulation of miR-154 confers poor prognosis in
CRC patients
Using the Kaplan-Meier method and log-rank test, we
found that the overall survival of CRC patients with low
miR-154 expression was significantly shorter than those
with high miR-154 expression (P = 0.006; Fig. 2). Besides,
the survival benefits were also found in those with
smaller tumor size (P = 0.026), early T classification (P =
0.032), negative N classification (P = 0.004), and earlyon miR-154 expression status. Patients in the low expression group
0.006, log-rank test)
Table 2 Univariate and multivariate analyses of prognostic factors in colorectal cancer
Variable Univariate analysis Multivariate analysis
HR 95 % CI P value HR 95 % CI P value
Age (years) 1.632 0.761–3.534 0.215 – – –
Gender 1.134 0.533–2.445 0.759 – – –
Histological grading 1.704 0.792–3.668 0.173 – – –
Tumor size 2.629 1.132–5.237 0.026 2.116 0.945–4.572 0.078
Depth of invasion 2.388 1.076–5.224 0.032 1.524 0.635–3.162 0.283
Lymph node metastasis 5.395 1.986–10.655 0.004 4.958 1.923–10.115 0.005
Clinical staging 2.973 1.202–6.488 0.015 5.232 1.998–12.685 0.001
MiR-154 3.178 1.436–9.356 0.006 2.825 1.006–5.132 0.022
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analysis enrolling abovementioned significant parameters
revealed that miR-154 expression (relative risk (RR)
2.825; P = 0.022), lymph node metastasis (RR 4.958; P =
0.005), and TNM stage (RR 5.232; P = 0.001) were inde-
pendent prognostic markers for overall survival of CRC
patients (Table 2).
Discussion
Dysregulation of miRs has been demonstrated to be in-
volved in tumorigenesis and progression in various types
of tumor; however, elucidation of their potential roles in
CRC remains in the early stage of development. In the
current study, we found that miR-154 was downregu-
lated in human CRC tissues compared with noncancer-
ous tissues. We also found that decreased miR-154
expression in CRC tissues was significantly correlated
with aggressive clinicopathological features. Moreover,
Kaplan-Meier analysis showed that CRC patients with
low miR-154 expression tend to have shorter overall sur-
vival. The multivariate analysis confirmed low miR-154
expression as a significant risk factor for overall survival,
indicating that miR-154 might be involved in CRC pro-
gression and could be used as a potential prognostic bio-
marker. To the authors’ knowledge, this is the first study
to investigate the clinical significance of miR-154 in a
large number of CRC patients.
miR-154 is located on human chromosome 14q32,
which is frequently lost in human cancers [20–22], and
miR-154 downregulation has been reported to play im-
portant roles in cancer progression. For instance, Wang
et al. found that restoration of intracellular miR-154 sup-
pressed tumor cell malignance and the G1/S transition
in hepatocellular cancer cells [18]. Zhu et al. indicated
low miR-154 expression levels in primary prostate can-
cer compared with nonmalignant samples [23]. Forced
expression of miR-154 significantly reduced the migra-
tory and invasive capabilities of prostate cancer cells.
Our study confirmed miR-154 downregulation in CRC
tissues, which is consistent with the previous study ofXin et al. [19]. The current data also demonstrated that
miR-154 might be related to the clinical outcome of pa-
tients with CRC, while Xin’s article reported the tumor-
suppressive function of miR-154 in CRC at the cell level.
Taken together, these results revealed that loss of miR-
154 might play a critical role in cancer formation and
progression, and miR-154 could act as a novel target for
cancer diagnosis and therapy.
It is now clear that miRs execute their oncogenic or
tumor suppressor functions by regulating the expression
of target genes [24]. Xin et al. identified the toll-like re-
ceptor 2 (TLR2) as a direct target of miR-154 in CRC
cells [19]. In their study, inhibition of TLR2 performed
similar effects with miR-154 overexpression on the bio-
logical behavior of CRC cells, and overexpression of TLR2
could significantly reverse the tumor-suppressive effects of
miR-154 on CRC cells. However, there is no “one-to-one”
connection between miRs and target mRNAs. An average
miR can have more than 100 targets [25]. Conversely, sev-
eral miRs can converge on a single transcript target [26].
TLR2 is not the only miR-154 target dysregulated in CRC.
Other functional targets of miR-154, such as cyclin D2
(CCND2), also modulate CRC pathogenesis [27, 28].
Therefore, the potential regulatory circuitry afforded by
miR-154 is enormous, and the accurate mechanisms on
how miR-154 influences CRC progression need further
clarification.
Conclusions
In summary, our present study showed that miR-154
was downregulated in CRC tissues, and low miR-154 ex-
pression was significantly correlated with aggressive clin-
icopathological features and worse prognosis. However,
the molecular mechanisms underlying miR-154 and the
regulation of CRC carcinogenesis have not been fully
elucidated. Therefore, this study is hypothesis generat-
ing, and further prospective analysis is worth doing.
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